Stern M, Herrmann R
Department of Hematology, University Hospital Basel, Switzerland.
Crit Rev Oncol Hematol. 2005 Apr;54(1):11-29. doi: 10.1016/j.critrevonc.2004.10.011.
After 30 years of development, therapy with monoclonal antibodies has started to realize its promise. Clinical use is most widespread in the field of oncology, where half of the agents approved for routine clinical use are employed and a large number of molecules are currently undergoing clinical trials. In the past 2 years alone, three new compounds-the radiolabeled antibody (131)I-tositumomab and two antibodies targeting growth factor receptors (bevacizumab and cetuximab)-have received FDA approval for indications in oncology. This review summarizes the development of this exciting treatment modality over the last three decades, examines the outcome of treatment with these new antibodies and others available for routine clinical use (i.e. rituximab, trastuzumab, alemtuzumab, gemtuzumab ozogamicin, (90)Y-ibritumomab tiuxetan) in standard indications and in experimental settings, and gives a brief outlook on possible future developments.
经过30年的发展，单克隆抗体疗法已开始兑现其承诺。临床应用在肿瘤学领域最为广泛，其中获批用于常规临床的药物有一半在此领域使用，并且大量分子目前正处于临床试验阶段。仅在过去两年中，就有三种新化合物——放射性标记抗体（131）I - 托西莫单抗以及两种靶向生长因子受体的抗体（贝伐单抗和西妥昔单抗）——已获得美国食品药品监督管理局（FDA）批准用于肿瘤学适应症。本综述总结了过去三十年这种令人兴奋的治疗方式的发展，研究了这些新抗体以及其他可用于常规临床的抗体（即利妥昔单抗、曲妥珠单抗、阿仑单抗、吉妥珠单抗奥唑米星、（90）Y - 伊布替膦酸钇）在标准适应症和实验环境中的治疗结果，并对未来可能的发展作简要展望。
